These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 36655608)

  • 1. Long-term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: Updated results from the randomized, placebo-controlled, phase 3 QUAZAR AML-001 trial.
    Wei AH; Döhner H; Sayar H; Ravandi F; Montesinos P; Dombret H; Selleslag D; Porkka K; Jang JH; Skikne B; Beach CL; Prebet T; Zhang G; Risueño A; Ugidos M; See WL; Menezes D; Roboz GJ
    Am J Hematol; 2023 Apr; 98(4):E84-E87. PubMed ID: 36655608
    [No Abstract]   [Full Text] [Related]  

  • 2. Management of adverse events in patients with acute myeloid leukemia in remission receiving oral azacitidine: experience from the phase 3 randomized QUAZAR AML-001 trial.
    Ravandi F; Roboz GJ; Wei AH; Döhner H; Pocock C; Selleslag D; Montesinos P; Sayar H; Musso M; Figuera-Alvarez A; Safah H; Tse W; Sohn SK; Hiwase D; Chevassut T; Pierdomenico F; La Torre I; Skikne B; Bailey R; Zhong J; Beach CL; Dombret H
    J Hematol Oncol; 2021 Aug; 14(1):133. PubMed ID: 34454540
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral Azacitidine Maintenance Therapy for Acute Myeloid Leukemia in First Remission.
    Wei AH; Döhner H; Pocock C; Montesinos P; Afanasyev B; Dombret H; Ravandi F; Sayar H; Jang JH; Porkka K; Selleslag D; Sandhu I; Turgut M; Giai V; Ofran Y; Kizil Çakar M; Botelho de Sousa A; Rybka J; Frairia C; Borin L; Beltrami G; Čermák J; Ossenkoppele GJ; La Torre I; Skikne B; Kumar K; Dong Q; Beach CL; Roboz GJ;
    N Engl J Med; 2020 Dec; 383(26):2526-2537. PubMed ID: 33369355
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival outcomes with oral azacitidine maintenance in patients with acute myeloid leukemia in remission by receipt of initial chemotherapy: subgroup analyses from the phase III QUAZAR AML-001 trial.
    Wei AH; Roboz GJ; Dombret H; Dohner H; Schuh AC; Montesinos P; Selleslag D; Bondarenko SN; Prebet T; Lai Y; Skikne B; Beach CL; Ravandi F
    Haematologica; 2023 Oct; 108(10):2820-2825. PubMed ID: 36951156
    [No Abstract]   [Full Text] [Related]  

  • 5. Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia.
    Roboz GJ; Montesinos P; Selleslag D; Wei A; Jang JH; Falantes J; Voso MT; Sayar H; Porkka K; Marlton P; Almeida A; Mohan S; Ravandi F; Garcia-Manero G; Skikne B; Kantarjian H
    Future Oncol; 2016 Feb; 12(3):293-302. PubMed ID: 26785287
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Azacitidine in combination with intensive induction chemotherapy in older patients with acute myeloid leukemia: The AML-AZA trial of the Study Alliance Leukemia.
    Müller-Tidow C; Tschanter P; Röllig C; Thiede C; Koschmieder A; Stelljes M; Koschmieder S; Dugas M; Gerss J; Butterfaß-Bahloul T; Wagner R; Eveslage M; Thiem U; Krause SW; Kaiser U; Kunzmann V; Steffen B; Noppeney R; Herr W; Baldus CD; Schmitz N; Götze K; Reichle A; Kaufmann M; Neubauer A; Schäfer-Eckart K; Hänel M; Peceny R; Frickhofen N; Kiehl M; Giagounidis A; Görner M; Repp R; Link H; Kiani A; Naumann R; Brümmendorf TH; Serve H; Ehninger G; Berdel WE; Krug U;
    Leukemia; 2016 Mar; 30(3):555-61. PubMed ID: 26522083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Azacitidine in AML: a treatment option?
    Huls G
    Blood; 2015 Jul; 126(3):283-4. PubMed ID: 26185114
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Survival outcomes in patients with acute myeloid leukaemia who received subsequent therapy for relapse in QUAZAR AML-001.
    Ravandi F; Döhner H; Wei AH; Montesinos P; Pfeilstöcker M; Papayannidis C; Lai Y; Wang K; See WL; de Menezes DL; Petrlik E; Prebet T; Roboz GJ
    Br J Haematol; 2024 Mar; 204(3):877-886. PubMed ID: 37952982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Azacitidine as the post-remission therapy for elderly patients with acute myeloid leukemia.
    Yamamoto R; Yokoyama A; Yoneda M; Ohashi K; Hosoda T; Kagoo T; Boku S; Ueno H; Yano T
    Ann Hematol; 2014 Dec; 93(12):2081-2. PubMed ID: 24863693
    [No Abstract]   [Full Text] [Related]  

  • 10. FDA Approval Summary: Oral Azacitidine for Continued Treatment of Adults with Acute Myeloid Leukemia Unable to Complete Intensive Curative Therapy.
    Jen EY; Wang X; Li M; Li H; Lee SL; Ni N; Przepiorka D; Vallejo J; Leong R; Ma L; Gehrke BJ; McLamore S; Theoret MR; de Claro RA
    Clin Cancer Res; 2022 Jul; 28(14):2989-2993. PubMed ID: 35325108
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azacitidine and lenalidomide as an alternative treatment for refractory acute myeloid leukemia: a case report.
    Todaro J; Bollmann PW; Rother ET; del Giglio A
    Sao Paulo Med J; 2015; 133(3):271-4. PubMed ID: 25250799
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
    Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia.
    Maurillo L; Buccisano F; Spagnoli A; Voso MT; Fianchi L; Papayannidis C; Gaidano GL; Breccia M; Musto P; De Bellis E; Del Principe MI; Lunghi M; Lessi F; Martinelli G; Venditti A
    Ann Hematol; 2018 Oct; 97(10):1767-1774. PubMed ID: 29947973
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Enasidenib plus azacitidine versus azacitidine alone in patients with newly diagnosed, mutant-IDH2 acute myeloid leukaemia (AG221-AML-005): a single-arm, phase 1b and randomised, phase 2 trial.
    DiNardo CD; Schuh AC; Stein EM; Montesinos P; Wei AH; de Botton S; Zeidan AM; Fathi AT; Kantarjian HM; Bennett JM; Frattini MG; Martin-Regueira P; Lersch F; Gong J; Hasan M; Vyas P; Döhner H
    Lancet Oncol; 2021 Nov; 22(11):1597-1608. PubMed ID: 34672961
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral azacitidine modulates the bone marrow microenvironment in patients with acute myeloid leukaemia in remission: A subanalysis from the QUAZAR AML-001 trial.
    Menezes DL; See WL; Risueño A; Tsai KT; Lee JK; Ma J; Khan R; Prebet T; Skikne B; Beach CL; Thakurta A; Gandhi A
    Br J Haematol; 2023 Jun; 201(6):1129-1143. PubMed ID: 36990798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Azacitidine for Front-Line Therapy of Patients with AML: Reproducible Efficacy Established by Direct Comparison of International Phase 3 Trial Data with Registry Data from the Austrian Azacitidine Registry of the AGMT Study Group.
    Pleyer L; Döhner H; Dombret H; Seymour JF; Schuh AC; Beach CL; Swern AS; Burgstaller S; Stauder R; Girschikofsky M; Sill H; Schlick K; Thaler J; Halter B; Machherndl Spandl S; Zebisch A; Pichler A; Pfeilstöcker M; Autzinger EM; Lang A; Geissler K; Voskova D; Sperr WR; Hojas S; Rogulj IM; Andel J; Greil R
    Int J Mol Sci; 2017 Feb; 18(2):. PubMed ID: 28212292
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prospective comparison of outcomes with azacitidine and decitabine in patients with AML ineligible for intensive chemotherapy.
    Zeidan AM; Fenaux P; Gobbi M; Mayer J; Roboz GJ; Krauter J; Robak T; Kantarjian HM; Novák J; Jedrzejczak WW; Thomas X; Ojeda-Uribe M; Miyazaki Y; Min YH; Yeh SP; Brandwein JM; Gercheva L; Demeter J; Griffiths EA; Yee KWL; Issa JJ; Bewersdorf JP; Keer H; Hao Y; Azab M; Döhner H
    Blood; 2022 Jul; 140(3):285-289. PubMed ID: 35507690
    [No Abstract]   [Full Text] [Related]  

  • 18. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oral azacitidine preserves favorable level of fatigue and health-related quality of life for patients with acute myeloid leukemia in remission: results from the phase 3, placebo-controlled QUAZAR AML-001 trial.
    Roboz GJ; Döhner H; Pocock C; Dombret H; Ravandi F; Jang JH; Selleslag D; Mayer J; Martens UM; Liesveld J; Bernal T; Wang MC; Yu P; Shi L; Guo S; La Torre I; Skikne B; Dong Q; Braverman J; Nehme SA; Beach CL; Wei AH
    Haematologica; 2021 Dec; 106(12):3240-3244. PubMed ID: 34551506
    [No Abstract]   [Full Text] [Related]  

  • 20. Ascertaining QUAZARs: slow-motion and light-speed development of oral azacitidine and decitabine.
    Feld J; Tremblay D; Navada SC; Silverman LR
    Leuk Lymphoma; 2023 Mar; 64(3):525-539. PubMed ID: 36370098
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.